Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 02/10/20 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | |
| 02/07/20 | 425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions |
|
13 | |
| 02/07/20 | 8-K | Current report filing |
|
13 | |
| 02/07/20 | S-4/A | Registration of securities issued in business combination transactions |
|
887 | |
| 01/13/20 | 425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions |
|
26 | |
| 01/13/20 | 8-K | Current report filing |
|
26 | |
| 01/06/20 | 8-K/A | Current report filing |
|
4 | |
| 12/27/19 | 8-K | Current report filing |
|
4 | |
| 12/10/19 | UPLOAD | SEC-generated letter |
|
1 | |
| 12/10/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 |
